Detailed explanation of how to use Aprecitentan: How to use the drug scientifically to improve the efficacy

Aprocitentan is a new oral dual endothelin receptor antagonist, mainly used to treat resistant hypertension , that is, patients who cannot control their blood pressure after taking three or more antihypertensive drugs (which must include diuretics). It effectively inhibits endothelin-1 (ET-1)-mediated vasoconstriction and sodium and water retention by simultaneously blocking ET-A and ET-B receptors, thereby achieving sustained antihypertensive effects. The drug is unique in that its mechanism of action is different from traditional antihypertensive drugs. It has obvious advantages in salt-sensitive hypertension, providing a new treatment path for patients with resistant hypertension.

In terms of specific usage, the currently recommended starting dose of aprecitentan is 1/2.5 mg orally once daily, depending on the patient's tolerance and blood pressure response. It is recommended to take it at the same time every day, with food or on an empty stomach. Before starting treatment, the patient's liver and kidney function should be evaluated, and caution should be used especially in patients with moderate to severe hepatic insufficiency or end-stage renal disease. For patients with mild hepatic and renal impairment, dose adjustment is generally not required.

It is worth noting that blood pressure changes, blood sodium, blood potassium and renal function indicators need to be monitored regularly while taking aprecitentan. Because this drug may cause fluid retention or mild anemia, doctors will consider whether to use it in combination with a diuretic or adjust the combined medication regimen based on individual responses. Clinical studies have shown that aprecitentan is well tolerated when used in combination with traditional antihypertensive drugs, and no significant drug interactions occur. In addition, it is recommended that women of childbearing potential take effective contraceptive measures while using this drug, as the endothelin system has potential effects on fetal development.

Although aprecitentan has confirmed its long-term antihypertensive effect and safety in multiple international phase III clinical studies, it is still in the clinical development stage in China. The specific launch time and instructions for details still need to pay attention to the latest developments of the National Medical Products Administration. During use, you should strictly follow the doctor's instructions and do not increase or decrease the dosage or stop the medication on your own to avoid affecting the blood pressure control effect.

Reference materials:https://go.drugbank.com/drugs/DB15059